Sanbio prices overseas share offering at ¥2,487 to fund clinical programs

Sanbio Company Limited, represented by president Keita Mori, announced the determination of the issue price and other details for its overseas new share offering, approved by the board of directors on November 6, 2025. The issue price is ¥2,487 per share, totaling ¥14,922,000,000. The total amount to be paid in is ¥14,265,840,000, with a payment per share of ¥2,377.64. The capital increase will be ¥7,132,920,000 for both stated capital and capital reserve. The payment date is set for November 21, 2025, and the delivery date for November 25, 2025.

The net proceeds, estimated at ¥14,202,000,000, will be allocated to several strategic initiatives. ¥1,393,000,000 will fund the establishment of a distribution system for Akougo in Japan by December 2027, including post-marketing clinical trials and safety infrastructure. ¥9,442,000,000 will be directed towards clinical trial expenses for the SB623 traumatic brain injury program in the U.S. market by December 2027.

Additionally, ¥3,367,000,000 is earmarked for clinical trial expenses for the SB623 cerebral infarction program in Japan by December 2027. Both the U.S. and Japan clinical trial allocations will cover planning, execution, and data analysis.